0001104659-14-085930.txt : 20141210
0001104659-14-085930.hdr.sgml : 20141210
20141210152930
ACCESSION NUMBER: 0001104659-14-085930
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141208
FILED AS OF DATE: 20141210
DATE AS OF CHANGE: 20141210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000890465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 870439579
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: (908) 450-5300
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Selisker Rachel R
CENTRAL INDEX KEY: 0001313793
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23272
FILM NUMBER: 141277903
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
STREET 2: 3RD FLOOR
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
4
1
a4.xml
4
X0306
4
2014-12-08
0
0000890465
NPS PHARMACEUTICALS INC
NPSP
0001313793
Selisker Rachel R
550 HILLS DRIVE
BEDMINSTER
NJ
07921
1
0
0
0
Common Stock
2014-12-08
4
M
0
23157
4.24
A
33057
D
Common Stock
2014-12-08
4
S
0
23157
34.5028
D
9900
D
Stock Options (right to buy)
4.24
2014-12-08
4
M
0
23157
0
D
2019-09-23
Common Stock
23157
1208
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.50 to $34.53, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
On September 23, 2009, the reporting person received a grant of 36,000 stock options under the Issuer's 2005 Omnibus Incentive Plan. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first anniversary of the date of grant and 6.25% every three months thereafter. As of the date of this filing, all 36,000 stock options have vested.
/s/ Rachel Selisker, by Christine Mikail as attorney in fact
2014-12-10